Search for other papers by David C Llewellyn in
Google Scholar
PubMed
Faculty of Life Sciences and Medicine, Kings College London, London, UK
Search for other papers by Rajaventhan Srirajaskanthan in
Google Scholar
PubMed
Department of Clinical Biochemistry, King’s College Hospital NHS Foundation Trust, Denmark Hill, London, UK
Search for other papers by Royce P Vincent in
Google Scholar
PubMed
Search for other papers by Catherine Guy in
Google Scholar
PubMed
Search for other papers by Eftychia E Drakou in
Google Scholar
PubMed
Neuroendocrine Tumour Unit, Kings Health Partners ENETS Centre of Excellence, Denmark Hill, London, UK
Search for other papers by Simon J B Aylwin in
Google Scholar
PubMed
Barts and the London School of Medicine, Centre for Endocrinology, William Harvey Institute, London, UK
Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
Faculty of Life Sciences and Medicine, Kings College London, London, UK
Search for other papers by John K Ramage in
Google Scholar
PubMed
Faculty of Life Sciences and Medicine, School of Life Course Sciences, Obesity Immunometabolism and Diabetes Group, King’s College London, London, UK
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
patients would CTN be of prognostic value, but no consistent patient characteristics were identified. Only three patients with hypercalcitonaemia in remission were followed up to 18 months after treatment initiation. Their CTN concentrations had only been
Division of Endocrinology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Search for other papers by Volha V Zhukouskaya in
Google Scholar
PubMed
APHP, Department of Endocrinology and Diabetology for Children, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
Search for other papers by Anya Rothenbuhler in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
IRCCS SDN, Naples, Italy
Search for other papers by Carolina Di Somma in
Google Scholar
PubMed
APHP, Department of Endocrinology and Reproductive Diseases, Bicêtre Paris-Saclay Hospital, Le Kremlin-Bicêtre, France
Paris Sud – Paris Saclay University, Faculté de Médecine, Le Kremlin-Bicêtre, France
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
APHP, Department of Molecular Genetics, Pharmacogenetics and Hormonology, Bicêtre Paris-Saclay Hospital, Le Kremlin-Bicêtre, France
Search for other papers by Séverine Trabado in
Google Scholar
PubMed
Hôpital Necker EnfantsMalades APHP, INSERM U1151, Paris, France
Search for other papers by Dominique Prié in
Google Scholar
PubMed
Search for other papers by Christelle Audrain in
Google Scholar
PubMed
Search for other papers by Anna Barosi in
Google Scholar
PubMed
Search for other papers by Christèle Kyheng in
Google Scholar
PubMed
APHP, Department of Endocrinology and Diabetology for Children, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
APHP, Department of Adolescent Medicine, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
Search for other papers by Anne-Sophie Lambert in
Google Scholar
PubMed
APHP, Department of Endocrinology and Diabetology for Children, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
Paris Sud – Paris Saclay University, Faculté de Médecine, Le Kremlin-Bicêtre, France
Search for other papers by Agnès Linglart in
Google Scholar
PubMed
. In contrary, we found an increased prevalence of overweight/obesity in children affected by XLH in each age group, despite the appropriate therapy. Regardless of the possible protective role of phosphate supplements at the treatment initiation, this
Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland
Search for other papers by Milica Popovic in
Google Scholar
PubMed
Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland
Search for other papers by Fahim Ebrahimi in
Google Scholar
PubMed
Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland
Search for other papers by Sandrine Andrea Urwyler in
Google Scholar
PubMed
Department of Biomedicine, University of Basel, Basel, Switzerland
Search for other papers by Marc Yves Donath in
Google Scholar
PubMed
Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland
Search for other papers by Mirjam Christ-Crain in
Google Scholar
PubMed
.01. Effect of IL-1 receptor antagonism on copeptin levels Median copeptin levels at baseline were 7.0 (IQR 4.2–11.2) pmol/L in the anakinra group and 7.2 (IQR 5.4–10.1) pmol/L in the placebo group. After treatment initiation, copeptin levels did not change
Search for other papers by Line Tang Møllehave in
Google Scholar
PubMed
Search for other papers by Marie Holm Eliasen in
Google Scholar
PubMed
Search for other papers by Ieva Strēle in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Allan Linneberg in
Google Scholar
PubMed
Université Libre de Bruxelles, Bruxelles, Belgium
Search for other papers by Rodrigo Moreno-Reyes in
Google Scholar
PubMed
Search for other papers by Ludmila B Ivanova in
Google Scholar
PubMed
School of Medicine, Zagreb, Croatia
Search for other papers by Zvonko Kusić in
Google Scholar
PubMed
Search for other papers by Iris Erlund in
Google Scholar
PubMed
Search for other papers by Till Ittermann in
Google Scholar
PubMed
Search for other papers by Endre V Nagy in
Google Scholar
PubMed
Department of Clinical Nutrition, Landspitali-National University Hospital, Reykjavik, Iceland
Search for other papers by Ingibjorg Gunnarsdottir in
Google Scholar
PubMed
Goldman School of Medicine, Ben Gurion University of the Negev, Beer Sheva, Israel
Search for other papers by Jonathan Eli Arbelle in
Google Scholar
PubMed
Search for other papers by Aaron Milton Troen in
Google Scholar
PubMed
Search for other papers by Valdis Pīrāgs in
Google Scholar
PubMed
Search for other papers by Lisbeth Dahl in
Google Scholar
PubMed
Search for other papers by Alicja Hubalewska-Dydejczyk in
Google Scholar
PubMed
Search for other papers by Malgorzata Trofimiuk-Müldner in
Google Scholar
PubMed
Search for other papers by João Jacome de Castro in
Google Scholar
PubMed
Search for other papers by Mafalda Marcelino in
Google Scholar
PubMed
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Search for other papers by Simona Gaberšček in
Google Scholar
PubMed
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Search for other papers by Katja Zaltel in
Google Scholar
PubMed
Universitat Autònoma de Barcelona, Barcelona, Spain
Search for other papers by Manuel Puig-Domingo in
Google Scholar
PubMed
Search for other papers by Lluis Vila in
Google Scholar
PubMed
Frölunda Specialist Hospital, Västra Frölunda, Sweden
Search for other papers by Sofia Manousou in
Google Scholar
PubMed
Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Wallenberg Centre of Molecular and Translational Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed
Search for other papers by Michael Bruce Zimmermann in
Google Scholar
PubMed
Search for other papers by Karen R Mullan in
Google Scholar
PubMed
Search for other papers by Jayne Valerie Woodside in
Google Scholar
PubMed
Search for other papers by Henry Völzke in
Google Scholar
PubMed
Search for other papers by Betina Heinsbæk Thuesen in
Google Scholar
PubMed
). Furthermore, during 2001–2009/2015 a fall in threshold for treatment initiation of thyroid hormone therapy was observed in both Great Britain and in Denmark leading to more prescriptions of thyroid hormone therapy, but the fall in treatment threshold was
Search for other papers by Giuseppe Lisco in
Google Scholar
PubMed
Search for other papers by Anna De Tullio in
Google Scholar
PubMed
Search for other papers by Olga Disoteo in
Google Scholar
PubMed
Search for other papers by Giuseppina Piazzolla in
Google Scholar
PubMed
Search for other papers by Edoardo Guastamacchia in
Google Scholar
PubMed
Search for other papers by Carlo Sabbà in
Google Scholar
PubMed
Search for other papers by Vincenzo De Geronimo in
Google Scholar
PubMed
Search for other papers by Enrico Papini in
Google Scholar
PubMed
Search for other papers by Vincenzo Triggiani in
Google Scholar
PubMed
( 13 , 14 , 15 , 16 ). Since then, regulatory agencies have recommended a careful and comprehensive anamnestic and thyroid imaging collection in candidate patients to receive GLP-1RAs before treatment initiation and through the follow-up to
Search for other papers by Lukas Plachy in
Google Scholar
PubMed
Search for other papers by Lenka Petruzelkova in
Google Scholar
PubMed
Search for other papers by Petra Dusatkova in
Google Scholar
PubMed
Search for other papers by Klara Maratova in
Google Scholar
PubMed
Search for other papers by Dana Zemkova in
Google Scholar
PubMed
Search for other papers by Lenka Elblova in
Google Scholar
PubMed
Search for other papers by Vit Neuman in
Google Scholar
PubMed
Search for other papers by Stanislava Kolouskova in
Google Scholar
PubMed
Search for other papers by Barbora Obermannova in
Google Scholar
PubMed
Search for other papers by Marta Snajderova in
Google Scholar
PubMed
Search for other papers by Zdenek Sumnik in
Google Scholar
PubMed
Search for other papers by Jan Lebl in
Google Scholar
PubMed
Search for other papers by Stepanka Pruhova in
Google Scholar
PubMed
) 5 (3–7) 5 (4–7) 0.85 Age at GH treatment initiation (years) 7 (5–9) 6 (5–9) 0.49 Average GH dose in the first year of treatment (ug/kg/day) 33 (32–36) 33 (31–35) 0.08 Average GH dose in the first year of treatment
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
Search for other papers by Wolfgang Högler in
Google Scholar
PubMed
Search for other papers by Agnès Linglart in
Google Scholar
PubMed
Search for other papers by Anna Petryk in
Google Scholar
PubMed
Search for other papers by Priya S Kishnani in
Google Scholar
PubMed
Search for other papers by Lothar Seefried in
Google Scholar
PubMed
Search for other papers by Shona Fang in
Google Scholar
PubMed
Search for other papers by Cheryl Rockman-Greenberg in
Google Scholar
PubMed
Search for other papers by Keiichi Ozono in
Google Scholar
PubMed
Search for other papers by Kathryn Dahir in
Google Scholar
PubMed
Search for other papers by Gabriel Ángel Martos-Moreno in
Google Scholar
PubMed
(asfotase alfa). Eligible patients were required to have available data on registry enrollment date, date of birth or age at registry enrollment, sex, asfotase alfa treatment start date (if treated), and at least one height measurement before treatment
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
School of Nursing and Midwifery, Institute of Clinical Sciences, University of Birmingham, UK
Search for other papers by Sherwin Criseno in
Google Scholar
PubMed
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Search for other papers by Helena Gleeson in
Google Scholar
PubMed
Search for other papers by Andrew A Toogood in
Google Scholar
PubMed
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Search for other papers by Neil Gittoes in
Google Scholar
PubMed
Search for other papers by Anne Topping in
Google Scholar
PubMed
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Search for other papers by Niki Karavitaki in
Google Scholar
PubMed
and international guidelines provide criteria for treatment initiation and monitoring; however, they do not offer any recommendation on the optimal duration of therapy ( 10 , 16 , 17 ). Consequently, many adults are receiving GH indefinitely, as the
1st Department of Propaupaedic Internal Medicine, Endocrine Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece
Search for other papers by Kosmas Daskalakis in
Google Scholar
PubMed
Search for other papers by Marina Tsoli in
Google Scholar
PubMed
Search for other papers by Anna Angelousi in
Google Scholar
PubMed
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Search for other papers by Evanthia Kassi in
Google Scholar
PubMed
Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed
Search for other papers by Denise Kolomodi in
Google Scholar
PubMed
Clinical Sciences Research Laboratories, Warwick Medical School, University of Warwick, University Hospital, Coventry, UK
Centre of Applied Biological & Exercise Sciences, Faculty of Health & Life Sciences, Coventry University, Coventry, UK
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Search for other papers by Anna Koumarianou in
Google Scholar
PubMed
duration of treatment. Patients were censored at the time they were lost to follow-up or at the end of the study, in September 2018. Multivariable Cox regression PFS analysis was employed to assess prognostic factors at treatment initiation for first
Search for other papers by Elizabeth Micks in
Google Scholar
PubMed
Search for other papers by Greta B Raglan in
Google Scholar
PubMed
Department of Obstetrics and Gynecology, Department of Research, University of Washington, Box 356460, 1959 NE Pacific Street, Seattle, Washington, USA
Search for other papers by Jay Schulkin in
Google Scholar
PubMed
CD002229 . ( doi:10.1002/14651858.CD002229.pub4 ). 88 Fournier A Mesrine S Boutron-Ruault MC Clavel-Chapelon F . Estrogen–progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation